TABLE 1

Phenotypic analysis results for patients who experienced virologic breakthrough at week 96 while adherent to the study drug

ParameterTAFTDF
No. of patients phenotyped (% of patients sequenced)18 (19)7 (15)
    Virologic breakthrough without nonadherence137
    Conserved site changes50
Mean EC50 fold change from baseline1.030.94
Range of fold change from baseline0.39–1.510.63–1.69